There has been a rapid rise in the use of intravitreal injections, such as anti-vascular endothelial growth factor (anti-VEGF) agents, performed over the past few years for the treatment of ocular neovascular diseases. This study aims to review the systemic and ocular adverse events among patients treated at a tertiary eye center over a period of 8 years. A retrospective review of all intravitreal injections of anti-VEGF performed over an 8-year period at a tertiary eye care center in Singapore was done. We report the frequency of systemic and ocular adverse events and compared it among the various anti-VEGF agents. A total of 14 001 intravitreal injections were performed on 2225 patients from January 1, 2007 to December 31, 2014, and this included 9992 bevacizumab (71.4 %), 3306 ranibizumab (23.6 %) and 703 aflibercept (5.0 %) injections. Systemic complications related to treatment were 26 (1.17 %) deaths (from any cause), of which 11 (0.49 %) were from fatal thromboembolic events, 7 (0.31 %) non-fatal thromboembolic events and two (0.09 %) serious non-ocular hemorrhage. Ocular complications included one (0.007 %) endophthalmitis, three (0.021 %) traumatic cataracts, and one (0.007 %) retinal detachment. Rates of death and thromboembolic events were similar among ranibizumab (lucentis), bevacizumab (avastin) and aflibercept (Eylea). The systemic and ocular complications associated with intravitreal injections among Asian patients at a tertiary eye center are relatively low and reflect the safety of the treatments.
This is a preview of subscription content, log in to check access.
We would like to acknowledge the doctors of the vitreo-retinal team and registrars from the National Healthcare Group Eye Institute (NHGEI), Tan Tock Seng Hospital Singapore, who assisted in the collection of the data. We would like to thank Hon Tym Wong and Rajesh Rajagopalan for their input, and Elizabeth Wong for statistical support. Dr. Colin Tan receives travel support from Bayer, Heidelberg Engineering, and Novartis. He also receives research support from National Healthcare Group Clinician Scientist Career Scheme Grant (CSCS/12005).
Dr. Xu Yanping has no financial support.
Wong TY, Liew G, Mitchell P (2007) Clinical update: new treatments for age-related macular degeneration. Lancet 370(9583):204–206CrossRefPubMedGoogle Scholar
Nicholson BP, Schachat AP (2010) A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 248(7):915–930CrossRefPubMedGoogle Scholar
Falavarjani KG, Modarres M, Nazari H (2010) Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy. Eye 24:717–719CrossRefPubMedGoogle Scholar
Detorakis ET, Agorogiannis G, Drakonaki EE, Tsilimbaris MK, Pallikaris IG (2012) Successful management of choroidal metastasis with intravitreal ranibizumab injection. Ophthalmic Surg Lasers Imaging 43:e47–e51PubMedGoogle Scholar
Nazari H, Parvaresh MM, Modarres M, Falavarjani KG (2010) Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol 248:1713–1718CrossRefPubMedGoogle Scholar
Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S (2011) Pharmaco therapy for neovascular age-related macula degeneration: an analysis if the 100 % 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 151(5):887–895CrossRefPubMedGoogle Scholar
CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE et al (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908CrossRefGoogle Scholar
Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC et al (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382:1258–1267CrossRefPubMedGoogle Scholar
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431CrossRefPubMedGoogle Scholar
The Diabetic Retinopathy Clinical Research Network (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193–1203CrossRefPubMedCentralGoogle Scholar
Storey P, Dollin M, Pitcher J (2014) The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology 121:283–289CrossRefPubMedGoogle Scholar
Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam WC (2012) Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 119(8):1609–1614CrossRefPubMedGoogle Scholar
Csaky K, Do DV et al (2009) Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol 148:647–656CrossRefPubMedGoogle Scholar
Tolentino M (2011) Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 56:95–113CrossRefPubMedGoogle Scholar
Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232–1239CrossRefPubMedGoogle Scholar
Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305(5):487–494CrossRefPubMedGoogle Scholar
Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G et al (2011) Intravitreal bevacizumab (avastin) versus ranibizumab (lucentis) for the treatment of age-related macula degeneration; a safety review. Br J Ophthalmol 95(3):308–317CrossRefPubMedGoogle Scholar
Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57–69CrossRefPubMedGoogle Scholar
Abraham P, Yue H, Wilson L et al (2010) Randomized, double-masked, sham- controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150:315–324CrossRefPubMedGoogle Scholar
Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G et al (2010) A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One 7(8):e42701CrossRefGoogle Scholar